Onyx's higher marketing expenses for Kyprolis seen as money well spent
This article was originally published in Scrip
Executive Summary
Onyx Pharmaceuticals won't offer sales projections for its multiple myeloma drug Kyprolis (carfilzomib), which won accelerated US FDA approval on 20 July for patients who failed treatment with at least two prior therapies (scripintelligence.com, 23 July 2012), but stock analysts offered their own opinions on the drug's value after the firm announced its second quarter 2012 financial results.